secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001823239-22-000042
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai Q2 revenue $242.7M (+11% YoY), net income $156.7M (+17%), Adj. EBITDA margin 78% record
--------------------------------------------------------------------------------

- Q2 revenue $242.7M (+11% YoY); net income $156.7M (+17%); Adj. EBITDA $188.5M (78% margin).
- Nucleic Acid Production revenue $225.2M (+17% YoY); base business (ex-COVID CleanCap) grew 27%.
- Biologics Safety Testing revenue $17.5M (-4% YoY); Protein Detection business sold in Sept 2021.
- Leadership additions: Pete Leddy as EVP/CAO, Kate Broderick SVP R&D, Jay Lochhead VP Quality & Regulatory.
- Signed DoD cooperative agreement to partly fund Nucleic Acid Production manufacturing expansion in San Diego.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323922000042/0001823239-22-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323922000042/mrvi-20220804.htm
  HTML page:      https://secwatch.observer/filing/0001823239-22-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer